New Zealand markets close in 4 hours 19 minutes

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
40.01-0.20 (-0.50%)
At close: 04:00PM EDT
39.84 -0.17 (-0.42%)
After hours: 07:45PM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    Royalty Pharma to Present at the UBS Global Healthcare Conference 2022

    NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the UBS Global Healthcare Conference 2022 on May 24, 2022 at 1:15 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical roya

  • GlobeNewswire

    Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Unique Business Model to Drive Value for All Stakeholders

    New capital deployment target of $10-12 billion over the next five yearsOutlook for 2020-2025 Adjusted Cash Receipts (1) (non-GAAP) CAGR raised to 11-14%Adjusted Cash Receipts (1) (non-GAAP) expected to grow 10% or more over this decade, positioning Royalty Pharma to be one of the fastest growing biopharma companiesDemand for capital to fund life sciences innovation to exceed $1 trillion in next decade NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) will host its ina

  • GlobeNewswire

    Royalty Pharma Reports First Quarter 2022 Results

    Net cash provided by operating activities (GAAP) of $460 million; Adjusted Cash Receipts(1) (non-GAAP) of $605 million Announced transactions of up to $450 million in Q1 20222022 guidance reaffirmed: Adjusted Cash Receipts(1) expected to be $2,225 to $2,300 million NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2022 and reaffirmed full-year 2022 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial mea